Fig. 5
From: Epidemiologic and clinical parameters of West Nile virus infections in humans: a scoping review
Clinical risk factors for developing neuroinvasive disease and for mortality in West Nile virus infection. Point estimates are measures of association (95% CI). Data on diabetes (a-b), hypertension (c-d), cancer (e-f) and immunosuppression (g-h) are shown
A. AFP/WNE v. WNF [58] | B. WNE [44] |
 WNE v. WNF [44] |  WNE [35] |
 WNE v. WNM/WNF [35] |  WNE/WNM [37] |
 WNE v. Non-WNV* [60] |  All [79] |
 WNE v. WNF [40] |  All [24] |
 WNM v. WNF [40] |  All [23] |
 WNND v. WNF [59] |  All [50] |
 WNND v. WNF [32] |  |
 WNF v. Asymptomatic [81] |  |
 All v. Non-WNV [49] |  |
C. AFP/WNE v. WNF [58] | D. WNE [44] |
 AFP/WNM v. WNF [58] |  WNE [35] |
 WNE v. WNM/WNF [35] |  WNE/WNM [37] |
 WNE v. WNF [44] |  All [23] |
 WNE v. WNF [40] |  All [79] |
 WNE v. Non-WNV* [60] |  |
 WNM v. WNF [40] |  |
 WNND v. WNF [59] |  |
 WNND v. WNF [32] |  |
 WNF v. Asymptomatic [82] |  |
 WNF v. Asymptomatic [81] |  |
 All v. Non-WNV [49] |  |
E. AFP/WNE v. WNF [58] | F. WNE [44] |
 WNE v. WNF [44] |  WNE [35] |
 WNE v. WNM/WNF [35] |  All [79] |
 WNE v. WNF [40] |  |
 WNE v. Non-WNV* [60] |  |
 WNM v. WNF [40] |  |
 All v. Non-WNV [49] |  |
G. WNE v. WNF [44] | H. AFP/WNE [58] |
 WNE v. WNM/WNF [35] |  WNE [44] |
 WNE v. Non-WNV* [60] |  WNE [35] |
 |  WNE/WNM [37] |
 |  All [23] |
 |  All [50] |
 |  All [79] |